Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05960929

InfasurfAero™ Versus Sham Treatment in Preterm Newborns With RDS

The purpose of this clinical study is to determine the effectiveness and safety of Infasurf® administered through the InfasurfAero™, a novel oral airway delivery device specifically designed to give Infasurf in a less complicated way and without the need for a breathing tube or interrupting nasal respiratory support.

Recruiting

Interested in participating?

Request Info

Key information

About this study

This single-dose, double-blind, random allocation, sham-control, clinical trial will recruit spontaneously breathing newborns with RDS stable on non-invasive nasal respiratory support. Enrolled clinical study subjects will be randomly allocated to receive respiratory air with Infasurf® (Intervention Arm) or respiratory air alone (Sham Control Arm) through the InfasurfAero™.

The objectives of this clinical study are to i) assess the effectiveness of a single dose of Infasurf administered through the InfasurfAero in preventing CPAP failure, and ii) assess the safety of Infasurf administered through the InfasurfAero.

Subjects will be enrolled at one of 10+ sites. 7 sites are currently recruited.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Inclusion criteria

include ALL of the following:

  • Written informed consent obtained by parent or legal representative prior to or after birth
  • Gestational age at birth ≥ 29 0/7 AND ≤ 35 6/7 weeks
  • Birthweight ≥ 1,000 AND ≤ 3,500 grams
  • Age ≥ 1 hour AND ≤ 6 hours
  • Clinical diagnosis of surfactant-deficient RDS, with EITHER i. a Silverman-Anderson Retraction Score ≥ 5 (in Room Air), OR ii. signs of respiratory distress (tachypnea, retractions, grunting) AND radiographic confirmation
  • Require CPAP
  • Respiratory Severity Score (RSS) ≥ 1.25 AND ≤ 2.4
  • If subject is >346/7 weeks' gestation a chest radiograph is required

Exclusion criteria

Exclusion criteria

are ANY of the following:

  • Surfactant administration prior to randomization
  • Mechanical ventilation prior to randomization
  • Major congenital anomaly (suspected or confirmed)
  • Abnormality of the airway (suspected or confirmed)
  • Respiratory distress presumed secondary to an etiology other than RDS (e.g., suspected pulmonary hypoplasia, pneumothorax, meconium aspiration syndrome, pneumonia, septic or hypovolemia shock, hypoxic ischemic encephalopathy)
  • Apgar score < 3 at 5 minutes of age
  • Umbilical cord gas pH <7.0 or BD > 10
  • Any condition that, in the opinion of the Investigator, would place the neonate at undue risk

Treatment and study plan

Infasurf Aero™

Combination Product

A single dose of Calfactant administered by pacifier interface by inhalation via the Infasurf Aero nebulizer at 6ml/kg.

Primary outcomes

  1. CPAP failure and or death

    Time frame: Within 1st week of age

    CPAP failure is defined as a respiratory severity score (RSS) (MAP x FiO2) >2.5 on two consecutive assessments at least 30 minutes apart, or an RSS > 2.4 and one or more of the following:

    (i) Silverman-Andersen respiratory severity score (https://www.thecalculator.co/health/Silverman-Score-Calculator-1125.html) of ≥ 5 despite respiratory support.

    (ii) Severe apnea (2 or more episodes per hour, or 1 or more episodes requiring manual positive pressure ventilation).

    (iii) Respiratory acidosis (pCO2 > 65 with a pH < 7.2 on blood gas). RSS will be the primary indicator of CPAP failure. However with the addition of the Silverman-Anderson scores, severe apnea and respiratory acidosis, CPAP failure may occur earlier than solely defined by RSS score.

Secondary outcomes

  1. Chronic lung disease and or death

    Time frame: 36 weeks post menstrual age (PMA).

    Chronic lung disease is defined as altitude adjusted oxygen requirement at 36 weeks post menstrual age.

  2. Incidence of MV

    Time frame: 36 weeks PMA

    Incidence of Mechanical Ventilation

  3. Duration of MV

    Time frame: 36 weeks PMA

    length of time of Mechanical Ventilation

  4. Incidence of intubation

    Time frame: 36 weeks PMA

    Any occurrence of tracheal intubation

  5. Incidence of invasive surfactant replacement therapy

    Time frame: 72 hours post birth

    any occurrence of liquid surfactant administration via and endotracheal tube

  6. Duration of non-invasive support

    Time frame: 36 weeks PMA

    Length of time of respiratory support other than Intubation

  7. Duration of supplemental oxygen

    Time frame: 36 weeks PMA

    Length of time any oxygen is administered.

Other outcomes

  1. Adverse events during surfactant administration.

    Time frame: Birth to 72 hours of age.

    Incidence of bradycardia and desaturation during surfactant administration.

Study contacts

Contact information is provided by the study sponsor or research team.

Corey Commaroto, RRT

CONTACT

[email protected]

7163614659

Dan Swartz, PhD

CONTACT

[email protected]

716428-3132

Sponsors and collaborators

Lead sponsor

ONY

Industry

Collaborators

  • Avania

Registry information

Official study title

InfasurfAero™ Versus Sham Treatment in Preterm Newborns With RDS: A Single-dose, Double-blind, Random Allocation, Sham-control, Clinical Trial

Acronym: Aero-05

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Jul 27, 2023
Registry last updated
Mar 30, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.